Overview

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Atrasentan
Hormones